Navigation Links
Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update
Date:11/7/2011

ncluding the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.ALEXZA PHARMACEUTICALS, INC.
(a development stage company)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(unaudited)Three Months EndedNine Months EndedSeptember 30,September 30,2011201020112010Revenue

$
,259$
744$
3,776$
744Operating expenses:Research and development

8,0516,65420,97722,508General and administrative

3,1092,6108,66411,474Total operating expenses

11,1609,26429,64133,982Loss from operations

(9,901)(8,520)(25,865)(33,238)Loss on change in fair value of contingent consideration liability

(3,000)8,509(3,300)7,338Interest and other income/ (expense), net

13193028Interest expense

(529)(599)(1,703)(1,024)Net loss

'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Alexza Pharmaceuticals to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
2. Alexza to Announce 2011 Third Quarter Financial Results on Monday, November 7, 2011
3. Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011
4. Alexza Pharmaceuticals to Present at the 18th Annual NewsMakers in the Biotech Industry Conference
5. Alexza and Grupo Ferrer Establish Partnership for the Commercialization of Adasuve™ (Staccato® Loxapine) in Europe and Latin America
6. Alexza Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
7. Alexza Announces Adasuve™ (Staccato® Loxapine) PDUFA Goal Date of February 4, 2012
8. Alexza Announces Resubmission of AZ-004 (Staccato® Loxapine) NDA
9. Alexza to Announce 2011 Second Quarter Financial Results on Monday, August 8, 2011
10. Alexza Reports 2011 First Quarter Financial Results and Provides Business Update
11. Alexza to Present at the MDB Bright Lights Conference 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... for Tuesday, December 9 at 11:00 am ET to Discuss ... , SOUTH SAN FRANCISCO, Calif., Dec. ... SNSS ), a biopharmaceutical company focused on the development and ... its studies of voreloxin in acute myeloid leukemia (AML) will ...
... 1 Vical Incorporated (Nasdaq: VICL ) announced ... Merck & Co., Inc. based on Merck,s planned initiation of ... (pDNA) cancer vaccine. The candidate vaccine is based on Vical,s ... (hTERT). hTERT is the subject of separate license agreement. , ...
Cached Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:7/9/2014)... Chase Cancer Center paint a relatively optimistic picture of ... that have spread to the chest wall or skin, ... the skin, regardless of size and whether they have ... and called "locally advanced" tumors, suggesting that they ... poor survival. Locally advanced breast cancers of this and ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... is one of the most important organs in the ... utilize our food properly this is its synthesis ... our organism this is its detoxification function. Lack ... food all damage the liver. The resulting diseased cells ... and life-threatening liver failure. According to the German Liver ...
Breaking Medicine News(10 mins):Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3
... always been stated time and again that smoking is injurious ... respiratory system. The effects of smoking may be understood by ... // lungs., ,Monoamine oxidase A (MAOA) is important in ... blood pressure. In a new study, researchers at the National ...
... disease which afflicts hundreds of elderly people may be a ... keep patients mentally agile and slow the crippling illness, say ... and not a normal process of ageing with phases of ... is past, the person slowly goes blank," N.M. Narula, president ...
... cancer is the most common cancer affecting men and occurs ... Men above the age of 50 years should undergo the ... // Prostate Specific Antigen, by monitoring the levels of PSA ... of the disease should begin regular prostate screening exams at ...
... published in the new issue of Archives of Facial ... with treatment procedures like laser therapy and other procedures. ... form an external birthmark and can be disfiguring, especially ... had presented the current treatment approaches for port-wine stains ...
... characterized by distorted, sickle shaped red blood cells. The disease ... the kidneys, spleen, and liver. The sickle cell disease is ... 1 in 500., ,Despite much clinical work, there is ... relieved, and the frequency and duration of the crises can ...
... San Francisco have found that eating five or more ... of pancreatic cancer by 50 per cent. ... were onions, garlic, beans, yellow vegetables (such as carrots, ... vegetables and cruciferous vegetables. Light-green vegetables, tomatoes and tomato ...
Cached Medicine News:Health News:Active Lifestyle Helps To Slowdown Illness In Alzheimer's Patients 2Health News:Hydroxyurea Treatment For Children With Sickle Cell Disease 2
... The Sidekick Testing System is the smallest ... System is there when you need it ... or suitcase, or simply in your purse or ... take wherever you go. And, because it's so ...
Inquire...
Inquire...
... Tube is a cost-effective method of providing ... your patient. The warming tube is ideal ... Cath. Lab., and Radiology. The CSZ Warming ... warm patients since it may be used ...
Medicine Products: